Cargando…

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease

Bronchodilators, including long-acting β(2)-agonists and long-acting muscarinic antagonists, are the mainstay for treatment of patients with chronic obstructive pulmonary disease (COPD) to prevent exacerbations or reduce symptoms. Formoterol is a highly selective and potent β(2)-agonist that relaxes...

Descripción completa

Detalles Bibliográficos
Autor principal:	Tashkin, Donald P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708267/ https://www.ncbi.nlm.nih.gov/pubmed/33273813 http://dx.doi.org/10.2147/COPD.S273497

Ejemplares similares

Formoterol in the management of chronic obstructive pulmonary disease
por: Steiropoulos, Paschalis, et al.
Publicado: (2008)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
por: Matera, Maria Gabriella, et al.
Publicado: (2016)

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2013)

Defining Disease Modification in Chronic Obstructive Pulmonary Disease
por: Halpin, David M.G., et al.
Publicado: (2009)

Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease
por: Jayanthi, Nalini, et al.
Publicado: (2022)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
por: Tashkin, Donald P, et al.
Publicado: (2010)

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

Small Airways, Big Problem: Extrafine beclomethasone/formoterol in asthma and chronic obstructive pulmonary disease
por: Hasan, Ashfaq, et al.
Publicado: (2021)

Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life
por: Tashkin, Donald P.
Publicado: (2023)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
por: Singh, Dave, et al.
Publicado: (2017)

Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease
por: Feng, Jun-fei, et al.
Publicado: (2018)

Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease: Results from a 1-Year Randomized Controlled Clinical Trial
por: Rennard, Stephen I., et al.
Publicado: (2012)

Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy
por: Tashkin, Donald P, et al.
Publicado: (2020)

Marijuana Use as a Risk Factor for Chronic Obstructive Pulmonary Disease: Not There Yet
por: Tashkin, Donald P., et al.
Publicado: (2023)

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
por: Singh, Dave, et al.
Publicado: (2016)

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
por: Doherty, Dennis E, et al.
Publicado: (2012)

Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease
por: Celli, Bartolome R, et al.
Publicado: (2012)

Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease
por: Zhao, Daguo, et al.
Publicado: (2018)

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study
por: Portillo, Edward C., et al.
Publicado: (2023)

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D
por: Lin, Yi-Hua, et al.
Publicado: (2017)

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
por: Voorham, Jaco, et al.
Publicado: (2018)

Real-world evidence effect of budesonide+formoterol Spiromax on patients with asthma and chronic obstructive pulmonary disease in Sweden
por: Janson, Christer, et al.
Publicado: (2019)

Evaluation of a Therapeutic Interchange from Fluticasone/Salmeterol to Mometasone/Formoterol in Patients with Chronic Obstructive Pulmonary Disease
por: Yip, Elaine, et al.
Publicado: (2016)

The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China
por: Huang, Kewu, et al.
Publicado: (2019)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2019)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2018)

Benefit:Risk Profile of Budesonide in Obstructive Airways Disease
por: Tashkin, Donald P., et al.
Publicado: (2019)

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2020)

Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease
por: Pelaia, Corrado, et al.
Publicado: (2023)

The Relation of Serum Myeloperoxidase to Disease Progression and Mortality in Patients with Chronic Obstructive Pulmonary Disease (COPD)
por: Park, Hye Yun, et al.
Publicado: (2013)

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2011)

Chronic Obstructive Pulmonary Disease is Not Associated with In-Hospital Mortality in COVID-19: An Observational Cohort Analysis
por: Toppen, William, et al.
Publicado: (2022)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases
por: Bayiz, Hulya, et al.
Publicado: (2015)

A comparison of the efficacy and safety of combined aclidinium bromide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis
por: Lu, Hong, et al.
Publicado: (2020)

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease
por: Usmani, Omar, et al.
Publicado: (2021)

An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
por: Zhang, Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9nk41h4nmucfjvc531cvcv67p4